Correction of haemorheological disturbances in myocardial infarction by diquertin and ascorbic acid.
In a model of the high blood viscosity syndrome, developed after myocardial infarction in rats, it was observed that a therapy of a combination of diquertin (20 mg/kg) and ascorbic acid (50 mg/kg) for a -period of 6 days, resulted in an improvement of haemorheological indices. The decrease in blood -viscosity was primarily due to an improved deformability of erythrocytes, and to some extent, due to a decrease in the content of plasma fibrinogen and erythrocyte aggregation.
Plotnikov
M B
MB
Laboratory of Blood Circulation Pharmacology, Institution for Pharmacology, Scientific Center of Russian Academy of Medical Sciences, Lenin St. 3, Tomsk 634028, Russia.
Aliev
O I
OI
Maslov
M Ju
MJ
Vasiliev
A S
AS
Tjukavkina
N A
NA
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001809:Blood Viscosity / Q000187:drug effects; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004903:Erythrocyte Aggregation / Q000187:drug effects; D005340:Fibrinogen / Q000187:drug effects; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D008517:Phytotherapy; D011794:Quercetin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D000975:Antioxidants; C473100:diquertin; D005340:Fibrinogen; D011794:Quercetin; D001205:Ascorbic Acid